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Abstract
Background: After more than half a century of modern psychopharmacology, with billions of dollars spent on
antidepressants annually world-wide, we lack good evidence to guide our everyday decisions in conducting
antidepressant treatment of patients with major depression. First we did not know which antidepressant to use as
first line treatment. Second we do not know which dosage we should be aiming at with that antidepressant.
Because more than half of the patients with major depression starting treatment do not remit after adequate trial
with the first agent, they will need a second line treatment. Dose escalation, augmentation and switching are the
three often recommended second line strategies but we do not know which is better than the others. Moreover,
we do not know when to start considering this second line treatment.
The recently published multiple-treatments meta-analysis of 12 new generation antidepressants has provided some
partial answers to the first question. Starting with these findings, this proposed trial aims to establish the optimum
1st line and 2nd line antidepressant treatment strategy among adult patients with a non-psychotic unipolar major
depressive episode.
Methods: SUN(^_^)D, the Strategic Use of New generation antidepressants for Depression, is an assessor-blinded,
parallel-group, multi-centre randomised controlled trial. Step I is a cluster-randomised trial comparing titration up to the
minimum vs maximum of the recommended dose range among patients starting with sertraline. The primary outcome
is the change in the Patient Health Questionnaire (PHQ)-9 scores administered by a blinded rater via telephone at week
1 through 3. Step II is an individually randomised trial comparing staying on sertraline, augmentation of sertraline with
mirtazapine, and switching to mirtazapine among patients who have not remitted on the first line treatment by week 3.
The primary outcome is the change in the PHQ-9 scores at week 4 through 9. Step III represents a continuation phase
to Steps I and II and aims to establish longer-term effectiveness and acceptability of the above-examined treatment
strategies up to week 25. The trial is supported by the Grant-in-Aid by the Ministry of Health, Labour and Welfare, Japan.
Discussion: SUN(^_^)D promises to be a pragmatic large trial to answer important clinical questions that every clinician
treating patients with major depression faces in his/her daily practices concerning its first- and second-line treatments.
Trial registration: ClinicalTrials.gov: NCT01109693
Background
Depression is costly
Major depression is the 1
st leading cause of disability
adjusted life years (DALY) lost excluding death, and the
3
rd leading cause of DALY including death in the world
according to the most recent WHO estimates [1].
Moreover, this burden is expected to rise in the next 20
years. According to the same estimates, major depres-
sion is currently the 1
st leading cause of DALY exclud-
ing death and the 2
nd leading cause of DALY including
death after cerebrovascular disease in Japan, comprising
approximately 6% of all DALY lost among its people.
Major depression is indeed one of the most prevalent
mental disorders in the United States and Europe, with
16.2% and 6.6% lifetime prevalence for American
women and men [2] and with 16.5% and 8.9% for Eur-
opean women and men [3]. In Japan, while the point
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most prevalent mental disorder for its people, affecting
one in 12 women (8.5%) and one in 29 men (3.5%) at
least once in their lifetime [4].
Both pharmacotherapy and psychotherapy have been
found to be equally effective in treating major depres-
sion [5] but the former remains the mainstay in every-
day clinical practices due to its greater availability,
tighter quality control and cheaper costs. Effective anti-
depressive agents include heterocyclic antidepressants
(HCA), monoamine oxidase inhibitors (MAOI), selective
serotonin reuptake inhibitors (SSRI), serotonin and nor-
adrenaline reuptake inhibitors (SNRI), noradrenalinergic
and specific serotonergic antidepressant (NaSSA) and
o t h e r s( s u c ha sb u p r o p i o n ) .T h ed r a m a t i cr i s ei nt h e
consumption of antidepressants in developed countries
in the past two decades has been mainly due to increase
in use of SSRI, SNRI and other new generation antide-
pressants, which now are the most commonly pre-
scribed antidepressants in the world [6]. In Japan the
market for antidepressants had been hovering around 15
billion yen (166 million US dollars) per year up to 1999
but has been expanding by some 20% annually, reaching
120 billion yen (1.3 billion US dollars) in 2009, in which
new generation antidepressants holds 89% share.
Evidence on 1
st line choice of antidepressants
There is no question that we need a specific, detailed
and appropriate guidelines in the treatment of major
depression. However, all the guidelines up to 2008,
including the one by the American Psychiatric Associa-
tion [7], the one by the Canadian Psychiatric Association
[8], the one by the National Institute of Clinical Excel-
lence in the United Kingdom [9] and the Japanese one
[10], recommend that the choice of antidepressants be
made “on the basis of adverse effect profiles, cost, and
patient preferences” [11] because there are differences in
side effect profiles but not in effectiveness among var-
ious antidepressants [12].
However, in 2009, the research group from Japan, Italy
and UK published the results of a systematic review of
117 RCTs (25928 subjects) of 12 new generation antide-
pressants in the acute phase treatment of major depres-
sion [13]. The Meta-analyses of New Generation
Antidepressants (MANGA) study is based on the most
comprehensive dataset of RCTs involving new genera-
tion antidepressants from the Cochrane Collaboration
Depression, Anxiety and Neurosis Group and makes use
of a new meta-analytic method called multiple-treat-
ments meta-analysis (MTM; also sometimes referred to
as network meta-analysis), which integrates data from
direct (when treatments are compared within a rando-
mised trial) and indirect comparisons (when treatments
are compared between trials by combining results on
how effective they are compared with a common com-
parator treatment). MTM thus allows a more precise
estimate of comparative effectiveness with narrower
confidence intervals than the traditional meta-analyses
because it makes use of all direct and indirect compari-
sons. MTM also minimizes the influence of publication
bias because a possible publication bias favoring a parti-
cular antidepressant can be counterbalanced by other
similar biases favoring other antidepressants when all
direct and indirect comparisons are combined through
MTM.
The MANGA Study observed many statistically signif-
icant and clinical meaningful differences among the 12
new generation antidepressants. In terms of efficacy,
mirtazapine, escitalopram, venlafaxine and sertraline
were among the top four drugs; in terms of acceptabil-
ity, escitaloporam, sertraline, bupropion and citalopram
were superior to the others. The authors concluded that
sertraline might be the best choice when starting treat-
ment for moderate to severe major depression in adults
because it has the most favorable balance between bene-
fits, acceptability, and acquisition cost.
Evidence on 2
nd line choice of antidepressants
Treatment of major depression is not easy because only
some 50% respond, i.e. achieve depression severity less
than half that at baseline, or only some 30% achieve
remission, i.e. return to an euthymic state, after treat-
ment with an adequate dose of antidepressant given for
an adequate duration [14]. When patients show no to
only partial response to the 1
st line treatment, 2
nd line
treatments must be initiated. Guidelines recommenda-
tions for the 2
nd line treatment include dose escalation,
switching to a different antidepressant possibly from a
different class and augmentation [9,15]. Unfortunately,
however, when many RCTs are planned and executed
with the purpose of drug approval by the regulatory
agency and as part of initial marketing strategy, evidence
on the 2
nd line treatment is much scanter than that on
the 1
st line.
First, with regard to dose escalation strategy, three
systematic reviews have been published and all con-
cluded that there is no evidence to suggest that dose
escalation increases efficacy in comparison with conti-
nuing on the same dosage after failure to respond to
the 1
st line antidepressant [16-18]. Next, with regard to
switching, we find two systematic reviews in the litera-
ture [19,20] both of which was able to identify only
one RCT that directly compared continuing on the
same drug and switching to another. In this trial, 104
patients not responding to 6 weeks of fluoxetine
20 mg/d were randomly assigned to further 6 weeks of
fluoxetine and switching to mianserin 60 mg/d;
the remission rate was 18% and 36%, respectively (p =
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pared, switching to venlafaxine after failure to respond
on an SSRI may be marginally better than switching to
another SSRI but there was no strong evidence to
recommend other classes of antidepressants [20].
Lastly, many RCTs and systematic reviews have been
published on various augmentation strategies. The
ones with most randomized evidence include lithium
augmentation [22], thyroid hormone augmentation
[23] and augmentation with atypical antipsychotics
[24]. Other options include augmentation with mirta-
zapine/mianserin [21,25,26] and augmentation with
pindolol [27].
Even less evidence can be found comparing these dif-
ferent 2
nd line strategies against each other than com-
paring each strategy with staying on the former
treatment. For example, the Sequenced Treatment
Alternatives to Relieve Depression (STAR*D), which was
funded by the NIMH and cost approximately 3 million
dollars, examined five switching strategies and four aug-
mentation strategies among the patients who had not
achieved remission to the 1
st line SSRI treatment but
was unable to compare switching versus augmentation
as few patients agreed to this randomization [28,29].
How to establish the optimum treatment strategy with
new generation antidepressants
Review of the literature has revealed that there are
indeed many urgent and critical clinical questions that
must be answered before clinicians can confidently and
competently administer pharmacotherapy for major
depression. Urgent because every practitioner encoun-
ters these clinical questions almost on a daily basis. Cri-
tical because answers to these clinical questions can
materially affect the patients’ lives. Bandolier (http://
www.medicine.ox.ac.uk/bandolier/index.html), an inde-
pendent evidence review journal in UK, concluded its
r e v i e wo nt h eM A N G AS t u d yb ys a y i n g ,“What the
meta-analysis provides is the raw material for the next
step, namely creating and testing a care pathway or
pathways for depression that provides good results for
the largest number of sufferers in the shortest time and
at the lowest cost.” (http://www.medicine.ox.ac.uk/ban-
dolier/booth/mental/cipriani.html). This proposed study
precisely aims to create and test this optimum care
pathway for depression.
1
st line treatment
According to the results of the MANGA Study, it is
wise to use sertraline as 1
st line treatment of major
depression in Japan because it represents the best bal-
ance in effectiveness and acceptability. However, practi-
tioners immediately face an important clinical decision
question at this stage, namely the problem of initial dos-
ing strategy. The standard dosage range for sertraline is
50-100 mg/d but should clinicians aim at achieving 50
mg/d or 100 mg/d in the initial dosing strategy? Papa-
kostas et al [30] published a systematic review of fixed-
dose trials comparing different starting doses of SSRIs.
In comparison with starting with the minimum of the
standard dose range, starting with the maximum of the
standard range may be more effective (RR = 1.12, 95%
CI: 0.99 to 1.27) but less acceptable (0.74, 0.54 to 1.00).
The response rate may increase from 51% to 54%, at the
expense of the dropout rate also rising from 10% to
17%. It must be noted that they compared different
starting doses, i.e. they administered the minimum or
maximum of the standard dose range from the very
beginning, and the dropouts are accounted for by last-
observation-carried forward which is bound to affect
and bias the results in an unknown way.
Can the initial dosing strategy to gradually increase
the dosage up to the maximum of the standard range,
recommended by many guidelines [8,10,31], be more
effective and at least not any more unacceptable than
t h es t r a t e g yt oa i ma tt h em i n i m u mo ft h es t a n d a r d
range? No one knows the answer. It is truly unaccepta-
ble that a clinical question as urgent as this, because
every single patient with major depression starting treat-
ment with antidepressant faces this decision point, is
not yet answered. We therefore planned an RCT to
answer this question.
2
nd line treatment
Even if we optimize the 1
st line antidepressant treatment
strategy, more than half the patients cannot achieve
remission [32]. What should we do as the 2
nd line treat-
ment, and when should we make this decision?
No systematic review has found evidence for dose
escalation and the present study will therefore not
examine this option. There are many RCTs examining
various augmentation strategies but only mirtazapine or
mianserin augmentation is allowable according to the
current Japanese regulations. As reviewed, we do not yet
know which of augmentation or switching is superior in
terms effectiveness and acceptability. Furthermore, we
do not yet know when we should make this clinical
decision to consider the 2
nd line treatment. Since each
clinical research can answer only a limited number of
well formulated clinical questions, this study will focus
on switching to mirtazapine, which was the most effec-
tive antidepressant according to the MANGA study, and
compare it to mirtazapine augmentation of SSRI, for
which a number of RCTs provide some support.
Switching to mirtazapine is a plausible option as the
2
nd line treatment for the following reasons. (i)
MANGA study showed mirtazapine may be the most
effective new generation antidepressant. Due to its less
favorable acceptability profile, it was not recommended
as the 1
st line treatment but, when the latter fails, it is
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sant. (ii) Switching is arguably to be preferred over aug-
mentation because combining two drugs may lead to
more known and unknown side effects than staying on
the same drug.
Mirtazapine augmentation of SSRI is another option
as the 2
nd line treatment for the following reasons. (i)
A number of RCTs have provided some evidence to
suggest its effectiveness. One small RCT randomly
assigned 26 patients who had not responded to SSRI,
bupropion or venlafaxine to augmentation either with
mirtazapine 15-30 mg/d or with placebo. The remis-
sion rates were 46% versus 13% (p = 0.068) [26].
Another RCT administered fluoxetine plus mirtazapine
or fluoxetine alone from the beginning of the acute
phase treatment and the remission rates were 25% vs
52% (p = 0.052) [33]. (ii) It makes sense pharmacologi-
cally to combine sertraline, which is an SSRI (specific
serotonin reuptake inhibitor), with mirtazapine,
which is a NaSSA (noradrenergic specific serotonergic
antidepressant). Mirtazapine increases noradrenaline
and serotonin release through antagonism of central
a2-adrenergic autoreceptors and heteroreceptors. Mir-
tazapine also exhibits antagonism to both 5-HT2A,5 -
HT2C and 5-HT3 receptors, which results in a net
increase in 5-HT1-mediated neurotransmission which
is believed to be the primary mediator of efficacy of
most antidepressant drugs. Antagonsim of the 5-HT2A
receptors has beneficial effects on sexual dysfunction
and insomnia, that of the 5-HT2B receptors on anxiety,
a n dt h a to f5 - H T 3 on gastrointestinal symptoms, all of
which constitute major side effects of SSRIs. (iii) Mir-
tazapine does not inhibit any liver enzymes and poses
very low risk of interaction with other drugs. Sertraline
exerts mild inhibition against CYP2D6 and 3A4 but is
generally believed to be a safer drug when adminis-
tered concomitantly with other drugs than many other
SSRIs.
Another very important clinical question to be
answered with regard to the 2
nd line treatment is when
to consider it. As far as practitioners are concerned, this
represents just as urgent a clinical question as that of
initial titration strategy but, to the best of the authors’
knowledge, no RCT has explicitly examined this issue
and the guidelines are ambiguous and self-contradictory.
For example, the guideline by the American College of
Physicians [11] recommends that clinicians modify treat-
ment if the patient does not have an adequate response
to pharmacotherapy within 6 to 8 weeks of the initiation
of therapy but this time frame appears to be based on
the average length of clinical trials conducted mainly for
drug approval. The NICE guidelines are self-contradic-
tory as it recommends 3-4 weeks at one place and 6-8
weeks at another before considering the 2
nd line treat-
ment alternatives [9]. We therefore decided to rando-
mize the patients with regard to the 2
nd line treatment
as early as 3 weeks and aimed to examine if considering
the 2
nd line treatment at this early stage may or may
not be beneficial in comparison with continuing the 1
st
line treatment for 6 more weeks.
Continuation treatment
The last but not least factor to be considered in con-
structing the optimum treatment strategy for the 1
st and
2
nd line treatments is the continuation treatment follow-
ing the acute phase treatment. A systematic review has
unambiguously demonstrated that discontinuing antide-
pressants at the end of acute phase treatment can dou-
ble the relapse/recurrence rates [34], and all the
guidelines recommend continuation treatment of at
least several months following acute phase treatment.
However, in reality, many patients do not stay on the
continuation phase [35]. It therefore follows that
another very important factor in deciding the 1
st and
2
nd line treatment strategies is how easy and acceptable
it is for patients to continue into the continuation treat-
ment after acute phase treatment, in addition to their
effectiveness and acceptability during the acute phase
treatment.
Aims
The current randomized trial aims to elucidate “path-
ways for depression that provides good results for the
largest number of sufferers in the shortest time and at
the lowest cost” (Bandolier 2009). More specifically, the
objectives of this trial are to examine the following
treatment options among patients with an untreated,
non-psychotic unipolar major depressive episode:
(1) When the 1
st line treatment is started with sertra-
line, which is better as an initial prescription strategy up
to 3 weeks in terms of effectiveness and safety (i.e. side
effects and treatment continuation), to titrate to the
lowest dosage of the effective range or to its highest
dosage?
(2) When the patients do not remit on the 1
st line
treatment at 3 weeks, which is better as acute phase
treatment up to 9 weeks in terms of effectiveness and
safety, to continue sertraline, to augment sertraline with
mrtazapine or to switch to mirtazapine?
(3) Which of the above strategies of 1
st and 2
nd line
treatments is better as acute phase and continuation
treatments up to 25 weeks in terms of effectiveness and
safety?
Methods
This is an assessor-blinded, parallel-group, multi-centre
randomized controlled trial.
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Participants will be recruited from among those visiting
the clinical trial sites according to the following eligibil-
ity criteria.
Inclusion criteria
1) The participant fulfills criteria for non-psychotic
unipolar major depressive episode (DSM-IV) within
one month before starting sertraline
2) Age between 25 and 75 on the day when sertra-
line is started
3) The major depressive episode is the focus of the
treatment and the treating physician has judged ser-
traline to be its appropriate 1
st line drug
4) Tolerability to sertaline has been ascertained after
3-16 days of treatment with sertraline 25 mg/d
5) The participant is able to understand and sign
written informed consent
6) The participant is available on the phone for
assessment of symptoms and side effects
Exclusion criteria
1) Having taken antidepressants, mood stabilizers
(lithium, valproate, carbamazepine), antipsychotics,
psychostimulants (methylphenidate, pemoline,
atmoxetine), electroconvulsive therapy, or depres-
sion-specific psychotherapies (cognitive-behavior
therapy, interpersonal therapy) within one month
before starting sertraline
2) History of schizophrenia, schizoaffective disorder
or bipolar disorder (DSM-IV) as judged by treating
physician
3) Current dementia, borderline personality disorder,
eating disorder or substance dependence (DSM-IV)
as judged by treating physician
4) Physical diseases which may contraindicate treat-
ment with sertraline or mirtazaapine
5) Allergy to sertraline or mirtazapine
6) Terminal physical diseases
7) Women who are pregnant or breastfeeding (if
there is a possibility of getting pregnant within 6
months of trial entry, participation is allowed only
after providing signed consent to avoid pregnancy
during the trial period)
8) Imminent high risk of suicide as judged by treat-
ing physician
9) Needing non-voluntary hospitalization
10) High probability of changing hospital due to
relocation etc within 6 months of trial entry
11) Cohabiting family members of research staff
members of the trial
12) Inability to understand written Japanese
Nb
1) A comprehensive systematic review and meta-ana-
lysis has shown that antidepressants increase suicidality
in comparison with placebo for people under age 25
but decreases suicidality for people aged 25 or older
[36].
2) Both males and females are accepted.
3) There is no eligibility criteria for severity of
depression as long as the participant meets the diag-
nostic criteria for major depression. Both outpatients
and inpatients are accepted.
4) Patients having taken benzodiazepine anxiolytics,
tandospirone, hydroxyzine, hypnotic medications,
traditional Kampo medications within one month
before starting sertraline are not excluded.
5) Patients having received psychotherapies other
than depression-specific ones (cognitive-behavior
therapy and interpersonal therapy) are not excluded.
6) Patients with physical diseases that the treating
physician judged would not interfere with treatment
with sertraline or mirtazapine are not excluded.
7) The participant will continue the trial even if his/
her diagnosis is changed after trial entry.
Trial Site Recruitment
Eligibility criteria for a trial site
A participating trial site must fulfill the following elig-
ibility criteria.
1) It must have a department of psychiatry or of psy-
chosomatic medicine.
2) The principal trial physician and all the participat-
ing trial physicians at the site must have understood
the study protocol (e.g. cluster randomization to 50
m g / do r1 0 0m g / do fs e r t r a l i n ea tS t e pI )a n dh a v e
agreed to collaborate.
Nb
A site-visiting CRC will be dispatched to a trial site
which
1) Is located within one hour at most approximately
from the regional centre
2) Has more than 100 first-visit patients with major
depression per annum
3) Has a separate room that the CRC can use for
informed consent and that the central assessor can
use for telephone assessment.
Such trial sites will open, if possible, “a trial clinic” on
a certain day of the week to facilitate patients’
participation.
Procedure for a trial site to participate
Each regional centre will recruit collaborating trial sites
(psychiatric private practice, department of psychiatry of
a general hospital, psychiatric hospital) in units of 4-5.
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the principal trial physician will seek approval from his/
her own IRB and then fax the document of approval to
the national centre office. The national central office
will examine the document(s) and return the review
results to the trial site principal physician by email.
If the trial site does not have its own IRB, the princi-
pal trial physician will send a proxy form to the IRB at
its regional centre and seek approval there.
Before the trial site starts recruiting the participants, all
the principal trial physician and the participating trial physi-
cians must attend the start-up meeting held either at the
trial site or at the national centre. The co-PI and CRC at the
regional centre will visit each trial site in order to make sure
that the site has finished the preparation and to rehearse the
EDC system and blinded central telephone assessment.
Procedures
T h eo v e r a l lp r o c e d u r eo ft h et r i a li ss h o w ni nF i g u r e s1
and 2.
Formulation of clinical questions
Clinical questions to be answered at each step can be
formulated as follows.
Step I Patients: Patients with non-psychotic unipolar
major depressive episode who had not received treat-
ment for the index episode before starting sertraline and
who tolerate sertraline 25 mg/d
Exposure1: Strategy to titrate sertraline up to the max-
imum of the effective range, i.e. 25 mg/d -> 50 mg/d ->
100 mg/d
Exposure2: Strategy to titrate sertraline upt to the
minimum of the effective range, i.e. 25 mg/d -> 50 mg/
d -> 50 mg/d
Outcomes: The primary outcome is the change
inPHQ9 scores at week 1 through week 3
The secondary outcomes include:
1) Change in BDI2 scores at week 1 through week 3
2) Proportion of remission (4 or less on PHQ9) at
week 3
3) Proportion of response (50% or greater reduction
on PHQ9) at week 3
4) Proportion of successful continuation of the allo-
cated treatment up to week 3
5) Change in FIBSER at week 1 through week 3
6) Change inPHQ9 at week1 through week 9
7) Change in BDI2 at week 1 through week 9
8) Proportion of remission (4 or less on PHQ9) at
week 9
9) Proportion of response (50% or greater reduction
on PHQ9) at week 9
10) Proportion of successful continuation of the allo-
cated treatment up to week 9
11) Change in FIBSER at week 1 through week 9
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Figure 1 Flow diagram of the trial.
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Page 6 of 2012) Suicidality as assessed with C-CASA between
week 1 and week 9
13) Manic/hypomanic/mixed episode between week
1 and week 9
14) Serious adverse events between week 1 and
week 9
Step II Patients: Patients whose major depressive epi-
sode did not remit (5 or more on PHQ9) at week 3 to
the 1
st line treatment with sertraline
Exposure1: Continue sertraline 50 mg/d or 100 mg/d
for 6 more weeks
Exposure2: Augment sertraline with mirtazapine 15-45
mg/d
Exposure3: Switch to mirtazapine 15-45 mg/d
Outcome: The primary outcome is the change in
PHQ9 at week4 through week 9
The secondary outcomes include:
1) Change in BDI2 at week 4 through week 9
2) Proportion of remission (4 or less on PHQ9) at
week 9
3) Proportion of response (50% or greater reduction
on PHQ9) at week 9
4) Proportion of successful continuation of the allo-
cated treatment up to week 9
5) Change in FIBSER at week 4 through week 9
6) Suicidality as assessed with C-CASA between
week 3 and week 9
7) Manic/hypomanic/mixed episode between week 3
and week 9
8) Serious adverse events between week 3 and
week 9
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Figure 2 Schedule of the planned assessments for Steps I, II and III.
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Page 7 of 20Step IIIa [exploratory analysis of continuation treat-
ment for Step I] Patients: Patients with non-psychotic
unipolar major depressive episode who had not received
treatment for the index episode before starting sertraline
and who tolerate sertraline 25 mg/d
Exposure1: Strategy to titrate sertraline up to the max-
imum of the effective range, i.e. 25 mg/d -> 50 mg/d ->
100 mg/d by week 3, then allocated to continue sertra-
line between week 3 and week 9, then treated at the dis-
cretion of the trial physician
Exposure2: Strategy to titrate sertraline up to the
minimum of the effective range, i.e. 25 mg/d -> 50 mg/
d -> 50 mg/d by week 3, then allocated to continue ser-
traline between week 3 and week 9, then treated at the
discretion of the trial physician
Outcome: The primary outcome is the proportion of
patients who continue the allocated treatment up to
week 25 and are in remission (4 or less on PHQ9) at
week 25
The secondary outcomes include:
1) Proportion of patients who continue the allocated
treatment up to week 25 and are showing response
(50% or greater reduction on PHQ9) at week 25
2) Rate of continuation of allocated treatments up to
week 25
3) Change in PHQ9 at week 1 through week 25
4) Change in BDI2 at week 1 through week 25
5) Suicidality as assessed with C-CASA between
week 1 and week 25
6) Manic/hypomanic/mixed episode between week 1
and week 25
7) Serious adverse events between week 1 and
week 25
Step IIIb [exploratory analysis of continuation treat-
ment for Step II] Patients: Patients whose major depres-
sive episode did not remit (5 or more on PHQ9) at
week 3 to the 1
st line treatment with sertraline
Exposure1: Continue sertraline 50 mg/d or 100 mg/d
for 6 more weeks, then treated at the discretion of the
trial physician
Exposure2: Augment sertraline with mirtazapine 15-45
mg/d up to week 9, then treated at the discretion of the
trial physician
Exposure3: Switch to mirtazapine 15-45 mg/d up to
week 9, then treated at the discretion of the trial
physician
Outcome: The primary outcome is the proportion of
patients who continue the allocated treatment up to
week 25 and are in remission (4 or less on PHQ9) at
week 25
The secondary outcomes include:
1) Proportion of patients who continue the allocated
treatment up to week 25 and are showing response
(50% or greater reduction on PHQ9) at week 25
2) Rate of continuation of allocated treatments up to
week 25
3) Change in PHQ9 at week 4 through week 25
4) Change in BDI2 at week 4 through week 25
5) Suicidality as assessed with C-CASA between
week 3 and week 25
6) Manic/hypomanic/mixed episode between week 3
and week 25
7) Serious adverse events between week 3 and
week 25
Pilot study
In order to test the feasibility of the study, a pilot study
will be run according to this same protocol between
December 2010 and October 2011. The pilot study will
be a multi-centre study involving:
￿ Nagoya City University Hospital and its affiliated
private practices and departments of psychiatry in a
general hospital
￿ Kochi Medical School Hospital and its affiliated
private practices, departments of psychiatry in a gen-
eral hospital and psychiatric hospitals
￿ Private practices in Yokohama
The Nagoya site will test recruitment using site CRCs,
the Kochi site will test recruitment using site CRCs and
direct recruitment by trial physicians, and the Yoko-
hama site will test recruitment using site CRCs dis-
patched from a commercial site management
organization. Feasibility and efficiency of these different
recruitment methods will be examined.
The pilot study will use data of the 1
st 200 patients up
to week 25. The pilot study will be reviewed by DSMB
who will advise the Steering Committee on the feasibil-
ity and safety of the study and on appropriateness of
continuing the study. The final decision about whether
to continue the study will be made by the Steering
Committee. Before continuing the study, the protocol
may be amended if necessary and additional trial sites
will be recruited.
Step I
Ascertaining eligibility criteria The trial physician and/
or site CRC will seek informed consent from a partici-
pant at week 1, i.e. 3-16 days after starting sertraline 25
mg/d. The “3-16 days” time frame was chosen to allow
two possible visit days to accommodate the participant’s
schedule at a site where the site CRC makes his/her vis-
its every week. After obtaining the written informed
consent, the trial physician or the site CRC makes a
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Page 8 of 20face-to-face interview or the central CRC or the central
rater will make a telephone interview to assess
1) PHQ9 at week 1
2) FIBSER at week 1
These week 1 assessment results will be entered into
the EDC along with the complete data on the “Eligibility
Form.”
Allocation to treatments Eligible participants will be
allocated 1:1 to the sertraline 50 mg/d arm and to the
sertraline 100 mg/d arm. We will employ cluster rando-
mization by trial site. This cluster randomization will be
made by the EDC system. The allocation will use the
minimization method adjusting for the number of prob-
able entries as judged by the principal investigator and
co-principal investigators (40 or more participants per
year vs less than 40 participants per year).
We employ cluster randomization for Step I for the
following reasons.
1) The comparison for Step I is between physician’s
choice of a strategy to titrate sertraline used as the
1
st line antidepressant up to the minimum effective
range or up to the maximum effective range. It is
therefore logical to randomize by physician.
2) In reality, because this is an open trial in which
the trial physician gradually titrates the dosage tak-
ing into account the side effects, having one patient
in the sertraline 100 mg/d arm and another in the
sertraline 50 mg/d arm may at the same time create
contamination in the doctor’s decisions. That is, if
we randomized by patient, the doctor might tend to
stick to his/her personally preferred titration sche-
dule regardless of the individual patient’s assignment
and reported side effects.
3) Likewise, having different doctors with different
titration policies within the same trial site might
cause unnecessary confusion among the physicians
and co-medical staff at the site.
4) Asking the participant to undergo individual ran-
domization twice might increase the barrier to
participation.
5) A number of previous studies have repeatedly
reported negligible to very small intra-cluster corre-
lation coefficients [37,38].
Treatments The trial physician will prescribe according
to either of the following schedule, depending on his/
her own allocated treatment strategy.
1) In the 100 mg/d arm, prescribe 50-75 mg/d (once
after dinner or before bedtime) for one week at
week 1, then prescribe 100 mg/d (once or divided
twice per day) for one week at week 2
2) In the 50 mg/d arm, prescribe 50 mg/d (once
after dinner or before bedtime) for one week at
week 1, then prescribe the same regimen for one
week at week 2
Outcome assessments The trial physician or the site
CRC will ask the participant to fill in BDI2 upon week 2
and week 3 visits. The CRC or the physician will enter
the data into EDC.
At week 3, the central rater will administer
1) PHQ9 at week 3
2) FIBSER at week 3
by telephone. The central CRC will obtain the
patient’s name and phone number and will keep the
rater blind to the name of the clinic and the treatment
the participant is receiving. This telephone assessment
will normally be conducted in a separate room after the
patient arrives at the clinic and before the consultation
with the trial physician, so that imminent suicidality
may be handled promptly and appropriately according
to the “Suicidality Management Manual.” If the patient
has dropped from the treatment, the telephone call will
be made to the mobile phone which he/she has pre-
viously registered upon entry into the trial. If strong sui-
cidal wishes are expressed, the central rater will follow
the “Suicidality Management Manual.”
Step II
Ascertaining eligibility criteria If the patient scores 5
or more on PHQ9 at week 3, as assessed by the central
rater, he/she will be randomized for Step II according to
the following procedures.
If the patient scores 4 or less on PHQ9 at week 3, he/
she will continue on the same regimen, and receive the
assessments at week 9 and week 25 as planned.
Allocation to treatments The patients scoring 5 or
m o r eo nP H Q 9a tw e e k3w i l lb ea l l o c a t e d1 : 1 : 1t ot h e
continue-sertraline arm, the mirtazapine augmentation
arm, and the mirtazapine switch arm. This randomiza-
tion will use the minimization method adjusting for (i)
site, (ii) whether 50% or greater reduction on PHQ9 is
achieved or not, and (iii) whether “moderate” or greater
impairment due to side effects is reported on item 4 of
FIBSER.
The central CRC will enter the necessary data from
P H Q 9a n dF I B S E Ri n t oE D C .T h eE D Cp r o g r a mw i l l
then output “The patient is making steady recovery.
Please continue with the same regimen” if the PHQ9
score is 4 or less, and any one of “Augment with mirta-
zapine. Please add mirtazapine 15 mg/d,”“ Switch to
mirtazapine. Decrease sertraline to half the current dose
and add mirtazapine 15 mg/d,” or “Continue with ser-
traline” if thePHQ9 score is 5 or more according to the
above randomization. The central CRC will fax the
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Page 9 of 20output to the trial physician and the site CRC, so that
the physician need not start up the computer every
time.
If the EDC server is down and/or the trial site cannot
use the EDC system for various reasons, the randomisa-
t i o nc a nb ed o n eb yc a l l i n gu pt h ec e n t r a lC R Co rt h e
data centre.
Treatments The details of the three intervention arms
are as follows.
1) Continue sertraline as specified by Step I cluster
randomization. Between week 4 and week 9, sertra-
line must be kept within the maximum as specified
by Step I cluster randomiza t i o n .I ft h ed o s a g eh a s
not reached this maximum (e.g. 100 mg/d) at week
3, it can be increased to this maximum (in this case,
100 mg/d) between week 3 and week 9.
2) Continue sertraline as specified by Step I cluster
randomization and add mirtazapine 15 mg/d at bed-
time to augment sertraline. After week 4, mirtaza-
pine can be given in 7.5-45 mg/d at bedtime.
Between week 4 and week 9, sertraline must be kept
within the maximum as specified by Step I cluster
randomization. If the sertraline dosage has not
reached this maximum (e.g. 100 mg/d) at week 3, it
can be increased to this maximum (in this case, 100
mg/d) between week 3 and week 9. Mirtazapine
should usually be started at 15 mg/d but can be
halved by the treating psychiatrist taking into
account age etc of the patient.
3) Decrease sertraline to half the current dose and
add mirtazapine 7.5-15 mg/d at bedtime in order to
switch to mirtazapine. Sertraline must be halved at
week 3 and stopped by week 4 or week 5 (sertraline
should no longer be prescribed at week 7 at the lat-
est), so that the patient will receive mirtazapine 7.5-
45 mg/d only between week 7 and week 9.
Outcome assessments The trial physician or the site
CRC will continue to ask the participant to fill in BDI2
at every visit between week 4 and week 9. The CRC or
the physician will enter the data into EDC.
At week 9, the central rater will administer
1) PHQ9 at week 9
2) FIBSER at week 9
by telephone. The central CRC will obtain the
patient’s name and phone number and will keep the
rater blind to the name of the clinic and the treatment
the participant is receiving. This telephone assessment
will normally be conducted in a separate room after the
patient arrives at the clinic and before the consultation
with the trial physician, so that imminent suicidality
may be handled promptly and appropriately according
to the “Suicidality Management Manual.” If the patient
has dropped from the treatment, the telephone call will
be made to the mobile phone which he/she has pre-
viously registered upon entry into the trial. If strong sui-
cidal wishes are expressed, the central rater will follow
the “Suicidality Management Manual.”
Step III
Ascertaining eligibility criteria All the participants
who have entered the trial are eligible.
Treatments All the available treatment guidelines for
depression recommends that the acute phase treatment,
if successful, be continued at least several months. All
the treatments between week 9 and week 25 are at the
treating physician’s discretion. He/she may continue
with the same regimen or completely change the regi-
men. Electroconvulsive therapy and depression-specific
psychotherapies can also be administered.
Outcome assessments The trial physician or the site
CRC will continue to ask the participant to fill in BDI2
at every visit between week 10 and week 25. The physi-
cian or the CRC will enter the data into EDC.
At week 25, i.e. approximately 6 months after trial
entry and 4 months after week 9 assessments, the cen-
tral rater will administer
1) PHQ9 at week 25
2) FIBSER at week 25
3) History of prescription up to week 25, especially
how long the treatment assigned at week 3 was
adhered to
by telephone. The central CRC will obtain the
patient’s name and phone number and will keep the
central rater blind to the name of the clinic and the
treatment the participant is receiving. This telephone
assessment will normally be conducted in a separate
room after the patient arrives at the clinic and before
the consultation with the trial physician, so that immi-
nent suicidality may be handled promptly and appropri-
ately according to the “Suicidality Management
Manual.” If the patient has dropped from the treatment,
the telephone call will be made to the mobile phone
which he/she has previously registered upon entry into
the trial. If strong suicidal wishes are expressed, the cen-
tral rater will follow the “Suicidality Management
Manual.”
Concurrent Treatments
Permitted concurrent treatments
The following medications are allowed throughout the
trial at the discretion of the trial physician.
1) Benzodiazepine anxiolytics and hypnotics
2) Tandospirone, hydroxyzine
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Page 10 of 203) Gastrointestinal and digestive drugs (except for
sulpiride)
4) Medications for concurrent physical diseases
5) Non-specific psychotherapies (psychotherapies
other than depression-specific CBT and IPT), exer-
cise therapy, music therapy, family psychoeducation
Prohibited concurrent treatments
Through Step I and Step II, the following treatments are
prohibited in principle. However, the patient’s safety
should be the utmost concern and takes priority over
everything else, all appropriate care should be given
depending on the patient’s condition.
1) Antidepressants other than sertraline or
mirtazapine
2) Antipsychotics
3) Mood stabilizers (lithium, valproate,
carbamazepine)
4) Depression-specific psychotherapies (CBT, IPT)
5) Electroconvulsive therapy
There is no prohibited treatments for Step III.
Stopping Rules For Participants & Trial Sites
Deviation from protocol treatment
The following cases will be considered deviation from
the trial protocol. The participant, however, will not be
considered to have dropped out of the study at this
stage and will receive the protocol assessments.
1) Prohibited concurrent treatments were adminis-
tered in Step I or II
2) The participant was not randomised within the
pre-specified time frame for week 3.
3) The participant cannot take any sertraline in Step
I.
4) The participant switches to manic/hypomanic/
mixed in Step I.
5) The participant turns out to suffer from bipolar
disorder, schizophrenia or dementia in Step II.
The treating physician is to judge whether 1) through
5) has occurred. If so judged, the physician should
immediately notify the site CRC, who will notify the
central office.
If 1) through 4) occurs in Step I, the randomization
for step II will not be made but assessment will
continue.
If 1) or 5) occurs in Step II, the patient will be ana-
lysed as randomized.
Stopping intervention
If the participant meets any one of the following condi-
tions, the trial physician will stop the protocol treatment
at his/her discretion. The participant, however, will not
be considered to have dropped out of the study at this
stage and will receive the protocol assessments.
1) The participant wishes to stop the protocol
treatment.
2) The trial physician judges that it is difficult to
continue the protocol treatment because of emer-
gence of serious adverse events (SAE) as defined
below.
3) The trial physician judges that the risk outweighs
benefit in continuing the protocol treatment even
when no SAE is reported.
4) The participant becomes pregnant and the trial
physician judges that the risk outweighs benefit in
continuing the protocol treatment.
5) The trial physician judges that it is inappropriate
to continue the protocol treatment for any other
reason.
Stopping assessment
If the participant meets any one of the following condi-
tions, he/she will never be contacted for assessments.
1) The participant withdraws consent to receiving pro-
tocol assessments, regardless of whether he/she is conti-
nuing the protocol treatment.
Dropping trial sites
If the trial site meets any of the following conditions, it
will be judged “dropout” and will no longer be able to
recruit patients. However, the patients who have already
entered the study will be followed-up.
1) The principal trial physician withdraws his
consent.
2) No study entry was made within 6 months.
3) The Steering Committee judges that it is inap-
propriate to continue recruitment at this site.
Assessments
Measures
Patient Health Questionnaire-9 (PHQ9) The Patient
Health Questionnaire was developed in 1999 as a self-
report version of the Primary Care Evaluation of Mental
Disorders (PRIME-MD) which aims at criteria-based
diagnosis of several mental disorders commonly seen in
primary care [39]. The depression module of the PHQ
is called PHQ9 and consists of the nine diagnostic cri-
teria items of the DSM-IV. Each item is rated between 0
= “Not at all” through 3 = “Nearly every day,” making
the total score range between 0-27. Excellent test-retest
reliability (ICC = 0.92) [40] and internal consistency
reliability (Cronbach’s alpha = 0.89) [39] have been
reported. Good construct validity has been demon-
strated through associations with various severity indices
[41]. The sensitivity to change is as good as or better
than extant scales [42].
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Page 11 of 20Kroenke and his colleagues have provided the follow-
ing rules of thumb for interpreting the continuous
PHQ9 scores [41].
0-4 no depression
5-9 mild depression
10-14 moderate depression
15-19 moderately severe depression
20- severe depression
The minimal clinically important difference, i.e. the
smallest difference in score that is considered to be a
clinically important intra-individual change, was estab-
lished to be 5 [42].
The PHQ9 should require less than one minute to fill
in for the patient and less than one minute to adminis-
ter for the clinician [41]. The Japanese version has been
established by Muramatsu through backtranslation [43].
In this trial, PHQ9 will be administered 5 times at
week1, week 3, week 9 and week 25. The central rater
will receive training in administering PHQ9 through
simulated interviews and will have demonstrated satis-
factory reliability. The blindness of the central rater as
to the participant’s treatment will be assessed by asking
the central rater to guess the allocated treatment at
week 3, 9 and 25 assessments.
Beck Depression Inventory-II (BDI2) BDI2 is a 21-item
self-report instrument to measure the severity of depres-
sion in adolescents and adults. Its first version was
developed in 1961 and slightly amended in 1979 but in
1996 a major revision was undertaken to make the scale
more congruent with the modern diagnostic criteria for
major depression. In its 40 years of usage, the BDI has
become one of the most widely used instruments for
detecting possible depression in normal populations and
for assessing severity of depression in diagnosed patients
[44].
The time frame for evaluation is set to the past 2
weeks including the day of assessment. Each item in
the BDI2 has a series of four statements, which
describe symptom severity along an ordinal continuum
from absent or mild (a score of 0) to severe (a score of
3). The total score therefore ranges from 0 through
63.
Good reliability and validity have been reported for
the original [45] as well as the Japanese version [46].
The original authors proposed the following rules of
thumb for interpreting the BDI2 scores [45]
0-13 Minimal
14-19 Mild
20-28 Moderate
29-63 Severe
Two subsequent studies from the US and from Japan
basically confirmed these interpretations [46,47].
A rough guide for interpreting the changes in BDI2
scores may be [46]
0-9 no or slight change, with 5 indicating a mini-
mally important clinical difference
10-19 moderate change
>= 20 large change.
Most patients are comfortable with this 21-item ques-
tionnaire and can complete them within 5-10 minutes.
In this trial, BDI2 will be filled in by the patient at
each visit.
Frequency, Intensity, and Burden of Side Effects Rat-
ing (FIBSER) FIBSER was originally used in STAR*D as
a global rating scale for side effects. This is an observer-
rated scale and the Japanese translation has not gone
through backtranslation.
Continuation of protocol treatment Continuation of
protocol treatment without stopping intervention or
stopping assessment as defined above is called “treat-
ment continuation.” In Step III, concurrent treatments
prohibited in Steps I and II can be used and this will
not constitute “treatment continuation.”
Timing of assessments
A s s e s s m e n t sa tw e e k3 ,9a n d2 5m a yb em a d ew i t h i n
the following time frames after week 1.
1) ±4 days for assessments at week 1 through 9
2) ±14 days for assessments after week 9
Assessment for week 3 must be made between -4 days
to +14 days of the planned date, and that for week 9
must also be made between -4 days to +14 days of the
planned date.
Data monitoring and site audit
Data monitoring T h ed a t ac e n t r ew i l lp r o v i d et h ef o l -
lowing data monitoring report to the Steering Commit-
tee and the DSMB every six months. The chair of the
DSMB will assess the data monitoring report, and if he/
she finds an ethical problem in the continuation of the
trial from the viewpoints of safety or effectiveness, he/
s h ew i l lc o n v e n et h eD S M Ba n da d v i s et h ep r i n c i p a l
investigator to change or stop the study.
The data monitoring report will include:
1) Progress of the trial regarding trial entry and fol-
low-up
2) Implementation of assessments (allocation will be
masked)
3) Incidence of serious adverse events (allocation will
be masked)
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Site audit Each site will be surveyed within 6 months
after the study commencement. The site audit team
nominated by the Steering Committee will survey the
sites according to the Site Audit Manual. The audit
team will report the results to the Steering Committee,
which will review them.
Reporting of adverse events and protection of
participants
Definition of adverse events
An adverse event is defined as any unwanted or unin-
tended sign (including laboratory exams), symptom or
disease seen in participants of the trial, regardless of the
causal relationship with the study intervention.
Reportings according to Pharmaceutical Affairs Act (1950
Law 145)
All the protocol interventions in the current trial are
within the approved dosage and administration in Japan
and will therefore have to follow the Japanese Pharma-
ceutical Affairs Act.
Adverse events will be assessed according to the
“Adverse Events Manual” which follows the Japanese
Ministry of Health, Labour and Welfare’s “Manual for
rating the severity of side effects by pharmaceutical pro-
ducts,” with an amendment to allow more detailed
assessment of suicidality according to Columbia Classifi-
cation Algorithm for Suicide Assessment (C-CASA)
[48].
Adverse events will be classified into:
Grade 1: minor side effects
Grade 2: neither major nor minor side effects
Grade 3: major side effects, i.e. side effects that may
lead to death or to enduring severe impairment
depending on the patient’sc o n d i t i o n sa n d
circumstances
All grade 3, and unforeseeable grade 2 adverse events
shall be reported to the relevant section of the Minis-
try of Health, Labour and Welfare as well as to the
national centre office. Foreseeable adverse events are
judged according to the package inserts of respective
drugs. Any grade 3 adverse events that occurred within
30 days of the completion of the protocol treatment
shall be reported to the Ministry and the national cen-
tre office. The reporting shall be done using the
attached “Reporting form on safety of pharmaceutical
products.”
The principal investigator, upon receiving the report,
will consult with the trial physician to discuss the course
of actions to be taken with regard to the patient in
question and also with regard to the study.
Reportings according to the Ethics Guideline for Clinical
Research (Ministry of Health, Labour and Welfare, revised in
2008)
When a serious adverse event occurs, the trial physician
must take all the necessary and appropriate measures to
ensure safety of the participant. He/she must also notify
the principal investigator immediately. The principal
investigator must notify co-principal investigators at all
the regional centres within 24 hours, and report to the
head of the clinical research institution (In the pilot
study, Director of Nagoya City University Hospital or
Director of Kochi Medical School Hospital) through the
co-principal investigators. The principal investigator
must also notify all the collaborators. The head of the
clinical research institution must report to its own IRB
and, if it concerns an unforeseeable serious adverse
event, must report to the Ministry of Health, Labour
and Welfare.
“A serious adverse event” is defined here as “an
adverse event that may lead to death or to enduring
severe impairment depending on the patient’s conditions
and circumstances” and will include:
1. Death
1.1. All deaths regardless of causal relationship
with the protocol treatment, if it is a death dur-
ing the protocol treatment
1.2. Deaths whose causal relationship with the
protocol treatment cannot be denied, if it is a
death within 30 days after completion of the pro-
tocol treatment.
2. Life-threatening event
3. Event leading to enduring and severe impairment
and dysfunction
When treatment is required, the trial physician will
provide and/or arrange appropriate treatments including
hospital admission.
Foreseeable adverse events according to the package
inserts
Sertraline Frequent side effects
Nausea (18.9%), somnolence (15.2%), dry mouth
(9.3%), headache (7.8%), diarrhea (6.4%), dizziness (5.0%)
etc.
Serious side effects
Serotonin syndrome (unknown frequency), malignant
syndrome (unknown frequency), convulsion (unknown
frequency), coma (unknown frequency), liver dysfunc-
tion (unknown frequency), SIADH (unknown fre-
quency), Lyell syndrome & toxic epidermal necrolysis
(unknown frequency), anaphylactoid symptoms
(unknown frequency)
Mirtazapine Frequent side effects
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Page 13 of 20Somnolence (50.0%), dry mouth (20.6%), fatigue
(15.2%), constipation (12.7%), increased AST/ALT
(12.4%)
Serious side effects
Serotonin syndrome (unknown frequency), agranulo-
cytosis/neutropenia (unknown frequency), convulsion
(unknown frequency), liver dysfunction/jaundice
(unknown frequency), SIADH (unknown frequency)
Stopping Rule For Study
The study will be discontinued by the Steering Commit-
tee (or the principal investigator in the case of an emer-
gency) upon advice from the DSMB if any of the
following conditions is met.
1) The causal relationship between any of the proto-
col treatments and serious adverse events including
death is established by this study or by any other
study.
2) Provision of study drugs becomes impossible for
any reason.
Data Management And Publication Policy
Data Management
The data management will be done by the data centre.
The electronic data is anonymized in a linkable record,
and the participants’ names and ID numbers will be
recorded only on non-electronic media (e.g. paper note-
book) and kept at each trial site.
The central CRC will check the progress of all the
entered participants every day by use of the EDC and
will contact the site CRC or the trial physician should
any doubt arise.
T h ed a t ac e n t r ew i l lp e r f o r ms i m i l a rc h e c k sa n dw i l l
contact the central CRC should any doubt arise.
Publication Policy
The protocol will be published, with TAF as first author.
The main papers stemming from Steps I, II and III,
especially the one from Step II, will be submitted to a
high impact journal. The collaborating researcher has
the right to be the first author of these papers in order
of their number of recruitment. TAF will remain the
corresponding author for all the papers. All the trial
principal physicians and the trial participating physicians
who have entered more than 10 patients will appear as
co-author of at least one paper.
Trial principal physicians, trial participating physicians
and other members of the Steering Committee, if they
do not appear as co-author, will be listed at the end of
the article. Such authors may be counted as co-authors
in some journals but not in others.
The results shall be reflected in treatment guidelines
and systematic reviews.
Study Period
The study period of this trial will be between December
2010 and March 2014, with the patient entry period
between December 2010 and September 2013.
The study period of the pilot study will be between
December 2010 and March 2012, with the patient entry
period between December 2010 and October 2011.
Statistical Analyses
Sample size calculation
Sample size for Step I Assuming an intra-cluster corre-
lation coefficient to be 0.05 [37,38], with alpha error at
0.05 and statistical power at 0.80, to detect a mean dif-
ference of 1 point on PHQ9 (SD = 5), i.e. to detect an
effect size of 0.2, we need 66 patients at each of 30 sites.
The total sample size is therefore 1980.
Sample size for Step II The clinical question for Step II
is the main hypothesis of this trial. Previous studies
using PHQ9 in the acute phase treatment of major
depression have shown that, on average, the PHQ9
scores will drop from 15 (SD = 5) at baseline to 10 (SD
= 6) at end of treatment, with a mean change of 5 (SD
= 5) [49-51]. We expect a difference of 20% (1 point) in
the PHQ9 change scores among the intervention arms
and consider this to be a clinically meaningful difference
in effect. With alpha error set at 0.05 and statistical
power at 0.80, in order to detect a between-group differ-
ence of 1 point (SD = 5) in the reduction of PHQ9
scores from baseline, we need 522 per group and 1566
in toto at Step II. Assuming a dropout rate of 20% and
a remission rate of 10% at week 3, we need 2175 partici-
pants for Step I.
One point difference in the mean change score on
PHQ9 corresponds with an effect size of 0.2. This is a
small effect according to Cohen’s rough rule of thumb
for effect size interpretation [52]. However, because the
present trial represents comparison among active treat-
ments and because the true effect size of antidepressants
over placebo appears to be around 0.3 [53] and the
average effect size of all the health interventions exam-
ined in the Cochrane Library appears to be between 0.3
and 0.4 [54], we consider this to be a clinically meaning-
ful difference in effectiveness worth detecting in a large
clinical trial. As a matter of fact, an effect size of 0.2 will
be translated into an NNT of 10 if the control event
rate is around 50% (e.g. response as defined usually by
50% or greater reduction in depression severity from
baseline) and 20 if the control event rate is around 20%
(e.g. remission of depression) [55]. They therefore repre-
sent clinically meaningful difference in effect.
The sample size will be revisited after completion of
the pilot study.
Sample size for Step III Step III represents continua-
tion treatment for Steps I and II, and will therefore be
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calculate sample size necessary to detect a significant
difference. However, we will calculate the obtained sta-
tistical power post-hoc.
Sample size for pilot study The pilot study is a feasibil-
ity study and needs no sample size calculation. The tar-
get sample size is 200. We will perform no statistical
analyses looking at the comparison arms at the end of
the pilot study, whose participants will therefore be
included in the main study unless there is a major
change in the study protocol.
Statistical analyses
Primary analyses For Step I, we will compare the ser-
traline 50 mg/d arm and the sertraline 100 mg/d arm
at an individual level. We will test whether the changes
in PHQ9 scores at week 1 through week 3 are statisti-
cally significantly different between the two arms.
Because Step I employs cluster randomization, we will
have to take into consideration intra-class correlation
coefficients.
For Step II, we will test whether the changes in PHQ9
scores at week 4 through week 9 are statistically signifi-
cantly different among the sertraline continuation arm,
the mirtazapine augmentation arm and the mirtazapine
switch arm. The null hypothesis that the changes are
not different among the treatment arms will be tested
by examining treatment effect parameters in the
repeated measures analyses of all the eligible subjects in
the ITT analysis. We will use random effects model tak-
ing into consideration the Step I randomization and
Step II randomization factors. We will examine interac-
tion effect of Step I cluster randomisation. The test will
be double-sided. The alpha error is set at 0.05 and sta-
tistical power at 0.80. We will impute the missing data
and carry out sensitivity analyses as necessary.
Secondary analyses We will perform secondary analyses
to supplement our primary analyses and to obtain more
elaborate understanding of our clinical questions. The
secondary analyses will use models similar to those of
the primary analyses. We will calculate relative risks and
their 95% confidence intervals for differences in propor-
tions. We will calculate hazard ratios and their 95% con-
fidence intervals for differences in treatment
continuation.
Details of the statistical analyses will be laid down in
the “Statistical Analysis Protocol”,w h i c hw i l lb ep r e -
pared by the statistician in the Steering Committee by
the time the analyses will be undertaken.
Interim analyses We will not perform interim analyses
to examine the study hypotheses for two reasons. First,
we are not expecting a huge effect size for the planned
comparisons and second, it is theoretically likely that
trials stopped early for benefit may overestimate the
true effect size.
However, we will examine the following aspects in
order to ascertain the feasibility of the study without
revealing the treatment allocation.
1) Number of entered subjects per trial site to calcu-
late the number of trial sites and the time necessary
to complete the intended study
2) The intra-cluster correlation coefficient will be
calculated in order to make sure that it is not very
different from the one assumed in this protocol. We
will re-calculate the sample size if necessary.
The analyses for the pilot study will be given in detail
in the “Statistical Analysis Plan.”
Ethical Aspects
Adherence to the study protocol and study manual
All the researchers participating in this trial will place
the participants’ safety and human rights above every-
thing else and will adhere by the study protocol and the
study manual so long as they do not undermine their
safety and human rights.
Regulations to be adhered to
All the researchers participating in this trial will abide
by the Declaration of Helsinki and its amendments as
well as the Ethics Guideline for Clinical Research (2008
revision, Ministry of Health, Labour and Welfare).
Procedures for informed consent
Before entry into the trial, the trial physician must
explain the following items using the written materials
and make sure that the participant has understood the
contents of the trial well. Written informed consent will
only then be obtained from the participant.
1) About clinical trials
2) Objectives of the trial
3) Name and position of the principal trial physician
and names of the participating trial physicians
4) Procedures and duration of the trial and what
happens after the trial is over
5) Advantages to be expected and disadvantages to
be anticipated
6) Other available treatment options
7) The participant can withdraw consent and stop
participating in the trial at any time
8) There is no disadvantage if the subject does not
participate in the trial or stops participating in the
trial.
9) Medical records that are related to this trial will
be seen by study personnel of this trial
10) Privacy will be maintained and protected
11) Contact address and method when the partici-
pant wants more information about the clinical trial
or when he/she feels unwell
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13) Fundings for this trial
14) Others
Protection of privacy
All the researchers and outsourcers of this trial must
strictly protect personal information of the participants
in adherence with the Ethics Guideline for Clinical
Research and the Private Information Protection Law.
Each trial site, each regional centre and the national
centre will collect information in anonymized and link-
able format. The data centre will not deal with personal
information of the participants. The linking information
for the participants is strictly managed at each trial site
or at the national centre without being computerized, i.
e. in paper format.
At week 3, week 9 and week 25, the central rater will
administer PHQ9 and FIBSER by telephone while being
blind to the participant’s allocated treatment. The cen-
tral CRC will arrange this blinded telephone call by
obtaining the participant’s name and telephone number
from each clinic every time. The central CRC will not
keep this privacy information at the national centre
office.
Approval by the IRB
This study has been approved by the Ethics Committee
of Kyoto University Graduate School of Medicine, the
Institutional Review Boards (IRBs) of Nagoya City Uni-
versity Hospital and of Kochi Medical School Hospital.
Each trial site will seek approval of the same protocol
if it has its own IRB. If there is no IRB, the trial site will
commission its approval to the IRB at Nagoya City Uni-
versity Hospital or at Kochi Medical School Hospital.
Compensation Insurance
All the protocol interventions in the current trial are
within the approved dosage and administration in
Japan. However, because the trial involves random
allocation, we will contract a private health insurance
to compensate for health hazards that have arisen due
to this trial. The contract will be between Kyoto Uni-
versity and Tokio Marine and Nichido Fire Insurance
Company. This insurance will cover only death or
grade 1 impairment or grade 2 impairment whose cau-
sal relationship with the trial cannot be negated.
Grades 3-14 impairments will not be covered by this
insurance but will be covered by the National Health
Insurance, which therefore can incur some copayment.
Because all the protocol interventions are within the
approved dosage and administration, any health
hazards may be object of the National Rescue Scheme
for Side Effects. If there is any negligence on the part
of the physician, it may be covered with the doctors’
liability insurance.
Study Organization
Steering Committee
The Steering Committee will hold online meetings every
two weeks and offline meetings every two months.
Principal investigator:
Toshiaki A. Furukawa, MD, PhD (Kyoto University
Graduate School of Medicine/School of Public Health,
Department of Health Promotion and Human Beahvior)
Co-principal investigators:
Tatsuo Akechi, MD, PhD, Norio Watanabe, MD, PhD
(Nagoya City University Graduate School of Medical
Sciences, Department of Psychiatry and Cognitive-Beha-
vioral Medicine)
Shinji Shimodera, MD, PhD (Kochi University Depart-
ment of Neuropsychiatry)
Mitsuhiko Yamada, MD, PhD, Masatoshi Inagaki, MD,
PhD (National Center for Neurology and Psychiatry,
Institute of Mental Health)
Trial statistician:
Naohiro Yonemoto, MPH (National Center for Neu-
rology and Psychiatry, Translational Medical Centre)
Data and Safety Monitoring Board: DSMB
DSMB will consist of three professionals in clinical trials
and in psychiatry, who are not involved in this trial: Dr
Teruhiko Higuchi (Psychiatrist, National Centre for
Neurology and Psychiatry), Professor Yoshio Hirayasu
(Psychiatrist, Yokohama City University) and Akiko
Kada (Biostatistician, National Cerebral and Cardiovas-
cular Center). The purpose of DSMB is to check the
data monitoring reports prepared by the data centre and
make recommendations, where necessary, to the princi-
pal investigator.
Research organization
Figure 3 shows the organizational structure for the pilot
study.
Data centre
T h ed a t ac e n t r ew i l lb ei nc h a r g eo fc o l l e c t i n ga n d
managing information independently from the research-
ers. The data centre will handle site registration, partici-
pant registration and allocation, monitor data entry,
manage quality assurance of data, manage quality con-
trol of data, prepare monitoring reports, and prepare
datasets for statistical analyses.
The data centre will make monitoring reports on the
progress of recruitment, progress of data collection and
adverse events to the Steering Committee and DSMB.
T h ed a t ac e n t r ew i l lb ee n t r u s t e dac o n t r a c tr e s e a r c h
organization to be chosen by public tender bidding.
National centre and Regional centres
The national centre office will be located within Depart-
ment of Health Promotion and Behavioral Medicine,
Kyoto University School of Public Health. It will have a
central rater, a CRC and a secretary.
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sity and Kochi University. There will be site CRCs who
will make weekly visits to participating trial sites to
assist informed consent procedures and to monitor and
enter clinical data.
Discussion
The SUN(^_^)D is an assessor-blinded, parallel-group,
mutli-centre randomised controlled trial sequentially
comparing active treatment options and combinations
currently approved for treatment of depression in Japan.
The prominent characteristics of the SUN(^_^) D
include the following.
First, the treatment arms in this trial are based on true
clinical uncertainty, because all of them are treatment
options currently approved by the regulatory bodies in
Japan. In other words, they represent treatment alterna-
tives from which both clinicians and their patients have
difficulties choosing at the present moment.
Second, the clinical questions to be examined in this
trial pertain to urgent and critical decision points for
which the world psychiatric and psychopharmacological
research community has hitherto failed to provide gui-
dance or answer to.
Third, the trial will take place mostly in front-line psy-
chiatric facilities such as private practices and depart-
ments of psychiatry of general hospitals from all over
Japan, where many if not most of the patients with major
depression receive their initial treatment. Because Japan
does not have the primary care system as represented by
the general practitioners in UK, these are the primary
care mental health services in Japan and the current trial
is thus expected to have maximum external validity with
respect to initial treatment of major depression in Japan.
Fourth, several important measures are built in to
ensure good internal validity for this pragmatic trial,
such as central randomization, blind assessment of
symptoms and side effects via telephone and adherence
to true intention-to-treat principle through differentia-
tion of discontinuation of protocol treatments and with-
drawal from study. Whether we can achieve the last
point will depend on whether we can follow up and
assess all the patients even when they stop or deviate
from the assigned treatments.
Data Center㻌
EDC by Contract Research 
Organization㻌
DSMB㻌
3 external reviewers㻌
2 meetings/year㻌
Steering Committee㻌
PI, co-PI, Biostatistician㻌
National Center
& Regional Centers
Central CRCs at Kyoto U㻌
Site CRCs at Nagoya City U㻌
Site CRCs at Kochi U㻌
Telephone assessment by 
central raters㻌
Informed consent and data entry by 
site CRCs㻌
Site Management 
Organization at Yokohama
Figure 3 Organizational structure for the pilot study
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Page 17 of 20As discussed in the Introduction, major depression
represents the greatest non-fatal burden of disease for
the humankind, with commensurate rise in spending on
the antidepressants world-wide. We maintain that this
must be accompanied by commensurate increase in evi-
dence base to guide their wise clinical administration.
For example, the total annual sales of antidepressants
amount to 120 billion yen (1.3 billion US dollars), and
we would like to advocate that at least 0.1% of this sum
be spent on public-domain pragmatic research of their
use for mood and anxiety disorders. Many urgent and
critical clinical questions can be answered with this
research funds only if the research can be simple and
pragmatic enough. We hope that SUN(^_^)D can be a
template for such future clinical trials, and that it ulti-
mately can provide good evidence to improve the treat-
ment guidelines for depression in the world.
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